Table 2.
Clinical characteristics of patients enrolled.
| Patient no | Sex | Age | Clinical form | Disease duration(month) | Location | Previous history |
|---|---|---|---|---|---|---|
| 1 | F | 48 | Fixed | 6 | Face | |
| 2 | F | 57 | Fixed | 3 | Face | |
| 3 | M | 61 | Fixed | 6 | Upper limbs | |
| 4 | M | 46 | Fixed | 2 | Lower limbs | |
| 5 | F | 50 | Fixed | 2 | Upper limbs | |
| 6 | M | 70 | Fixed | 1 | Face | |
| 7 | F | 48 | Fixed | 2 | Upper limbs | |
| 8 | F | 48 | Fixed | 12 | Chest | |
| 9 | M | 68 | Lymphocutaneous | 4 | Face | |
| 10 | F | 59 | Lymphocutaneous | 3 | Upper limbs | |
| 11 | F | 65 | Fixed | 8 | Face | |
| 12 | F | 51 | Fixed | 12 | Face | hypertension |
| 13 | F | 52 | Fixed | 6 | Face | |
| 14 | F | 42 | Fixed | 24 | Upper limbs | |
| 15 | F | 47 | Lymphocutaneous | 7 | Face | |
| 16 | M | 74 | Lymphocutaneous | 6 | Upper limbs | hypertension |
| 17 | M | 65 | Lymphocutaneous | 12 | Face | hypertension |
| 18 | M | 73 | Lymphocutaneous | 4 | Upper limbs | |
| 19 | M | 47 | Lymphocutaneous | 4 | Face | |
| 20 | F | 66 | Fixed | 10 | Upper limbs | |
| 21 | F | 81 | Fixed | 12 | Face | |
| 22 | F | 52 | Lymphocutaneous | 2 | Neck | |
| 23 | F | 75 | Lymphocutaneous | 12 | Face | hypertension |
| 24 | M | 48 | Fixed | 3 | Face | |
| 25 | F | 18 | Fixed | 2 | Face | ointment |
| 26 | F | 40 | Fixed | 3 | Face | ointment |
| 27 | F | 39 | Fixed | 7 | Face | |
| 28 | F | 63 | Fixed | 12 | Upper limbs | |
| 29 | M | 50 | Fixed | 7 | Face | |
| 30 | F | 30 | Lymphocutaneous | 2 | Upper limbs | |
| 31 | F | 52 | Fixed | 24 | Face | |
| 32 | F | 52 | Lymphocutaneous | 6 | Upper limbs | ointment |
| 33 | F | 46 | Fixed | 4 | Face | |
| 34 | F | 50 | Fixed | 9 | Face | |
| 35 | F | 54 | Fixed | 2 | Face | |
| 36 | F | 40 | Lymphocutaneous | 2 | Upper limbs | |
| 37 | M | 29 | Lymphocutaneous | 4 | Face | |
| 38 | F | 44 | Fixed | 12 | Chest | |
| 39 | F | 30 | Lymphocutaneous | 1 | Face | |
| 40 | F | 56 | Fixed | 6 | Face | |
| 41 | M | 48 | Fixed | 12 | Face | |
| 42 | M | 46 | Lymphocutaneous | 2 | Face | |
| 43 | F | 47 | Fixed | 12 | Face | |
| 44 | F | 37 | Fixed | 2 | Face | |
| 45 | M | 60 | Fixed | 1 | Face | |
| 46 | M | 53 | Lymphocutaneous | 3 | Upper limbs | hypertension |
| 47 | F | 53 | Fixed | 12 | Back | |
| 48 | F | 60 | Fixed | 7 | Upper limbs | |
| 49 | M | 50 | Fixed | 6 | Upper limbs | |
| 50 | F | 51 | Lymphocutaneous | 3 | Upper limbs | |
| 51 | F | 65 | Lymphocutaneous | 4 | Face | |
| 52 | M | 32 | Fixed | 10 | Chest | |
| 53 | M | 51 | Fixed | 6 | Face | |
| 54 | M | 77 | Fixed | 1 | Face | |
| 55 | M | 65 | Fixed | 6 | Upper limbs | |
| 56 | F | 65 | Fixed | 2 | Upper limbs | Oral itraconazole |
| 57 | F | 54 | Fixed | 6 | Face | |
| 58 | M | 45 | Fixed | 3 | Upper limbs | |
| 59 | F | 46 | Fixed | 12 | Face | |
| 60 | M | 52 | Fixed | 12 | Lower limbs | |
| 61 | F | 66 | Lymphocutaneous | 4 | Upper limbs | |
| 62 | M | 53 | Fixed | 6 | Upper limbs | |
| 63 | F | 73 | Fixed | 6 | Upper limbs | |
| 64 | F | 48 | Lymphocutaneous | 6 | Face | |
| 65 | M | 64 | Fixed | 4 | Upper limbs | |
| 66 | F | 79 | Fixed | 12 | Upper limbs | |
| 67 | F | 41 | Fixed | 6 | Upper limbs | |
| 68 | F | 36 | Fixed | 36 | Neck |
No.51 to No.68 subjects were included in from 2020.07.10.